Literature DB >> 10365150

Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC).

O A Brinkmann1, F Bruns, F J Prott, L Hertle.   

Abstract

PURPOSE: Bone metastases or local recurrences are widely viewed as poor prognostic signs for successful immunotherapy for metastatic renal cell carcinoma (RCC), and even partial remission is a rarity. We assessed the efficacy of the combination of radio and chemo-immunotherapy for bone metastases or local recurrences form RCC.
MATERIALS AND METHODS: From February 1994 until September 1997 twelve patients with progressive renal cell carcinoma (9 with bone metastases and 3 with local recurrence) were treated with a combination of chemo-immunotherapy and radio therapy.
RESULTS: Four out of twelve patients achieved complete remission (CR), one patient had a partial remission (PR), three were stable and four had disease progression under radio therapy and chemo-immunotherapy. Yet three pts. died of the disease. The toxicity symptoms according to WHO ranged between grade 2 and grade 3.
CONCLUSION: Our data suggest that the combination of radio therapy and chemo-immunotherapy may induce a synergistic antitumor effect for the treatment of bone metastases or local recurrences from renal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10365150

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

Review 1.  Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach.

Authors:  Shankar Siva; Gargi Kothari; Alexander Muacevic; Alexander V Louie; Ben J Slotman; Bin S Teh; Simon S Lo
Journal:  Nat Rev Urol       Date:  2017-06-20       Impact factor: 14.432

Review 2.  Immunotherapy in metastatic renal cell carcinoma.

Authors:  Karl Rohrmann; Michael Staehler; Nikolas Haseke; Alexander Bachmann; Christian G Stief; Michael Siebels
Journal:  World J Urol       Date:  2005-04-02       Impact factor: 4.226

Review 3.  [Therapy strategies for advanced renal cell carcinoma].

Authors:  M Staehler; N Haseke; G Schöppler; T Stadler; C Adam; C G Stief
Journal:  Urologe A       Date:  2006-01       Impact factor: 0.639

4.  Treatment of bone metastases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation.

Authors:  Olaf Anselm Brinkmann; Frank Bruns; Georg Gosheger; Oliver Micke; Lothar Hertle
Journal:  World J Urol       Date:  2005-04-19       Impact factor: 4.226

5.  Lymphokine-activated killer cell susceptibility and adhesion molecule expression of multidrug resistant breast carcinoma.

Authors:  Burhan Savas; Pauline E Kerr; Hugh F Pross
Journal:  Cancer Cell Int       Date:  2006-11-03       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.